MuSK Myasthenia 1000 Study
NCT06259071 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2024-02-14
Summary
The MuSK myasthenia gravis 1000 study seeks to collect saliva samples from 1000 subjects with laboratory confirmed diagnosis of MuSK myasthenia to identify genetic variations associated with MuSK MG. The data collected may be used by researchers to gain a better understanding of the cause of MuSK MG and to identify biomarkers and targeted therapy for MuSK MG.
Conditions
- Myasthenia Gravis
- MuSK MG
- MuSK Myasthenia Gravis
Sponsors & Collaborators
-
Myasthenia Gravis Rare Disease Network
lead NETWORK
Eligibility
- Min Age
- 7 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-08-23
- Primary Completion
- 2025-08-23
- Completion
- 2025-12-31
Countries
- United States
Study Locations
More Related Trials
-
Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation
NCT02511041 ·Status: TERMINATED ·Phase: PHASE1
-
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy
NCT01547767 ·Status: COMPLETED
-
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
NCT00048620 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics
NCT01675674 ·Status: TERMINATED
-
Unrelated Donor BMT for Treatment of Patients With PGK Deficiency
NCT00592540 ·Status: COMPLETED ·Phase: NA
-
Studies in Patients With Tuberous Sclerosis Complex
NCT03276195 ·Status: COMPLETED
-
Study of rhASB in Patients With Mucopolysaccharidosis VI
NCT00104234 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI
NCT00048711 ·Status: COMPLETED ·Phase: PHASE2
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
NCT05176379 ·Status: RECRUITING ·Phase: PHASE4
-
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
NCT05967351 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
NCT01218659 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
NCT06549400 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
NCT06539624 ·Status: RECRUITING ·Phase: NA
-
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
NCT05025241 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Follow-Up for RGX-121
NCT04597385 ·Status: UNKNOWN
-
Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease
NCT01230801 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®
NCT00731081 ·Status: COMPLETED
-
A Study of Patients With Fabry Disease (US Specific)
NCT06906367 ·Status: RECRUITING
-
A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ
NCT05422482 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
NCT06078553 ·Status: RECRUITING
-
Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension
NCT02531217 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)
NCT05543174 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease
NCT00515398 ·Status: COMPLETED
-
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
NCT06241950 ·Status: TERMINATED ·Phase: PHASE1
-
Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia
NCT03810690 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2